 |
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
|
|||||||
|
||||||||
|
|
|
|
|
|
|
|
|
|
Gateway® |
||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
 Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
Location of features
attL1 site: 14-113
Kozak translation initiation site: 129-139
HyPer-AS: 136-1572
attL2 site: 1598-1697
Kanamycin resistance gene: 2922-3716
pUC origin of replication: 4301-4944
Notice to Purchaser:
The HyPer-related materials (also referred to as "Products") are intended for research use only. These products are covered by Evrogen Patents and/or Patent applications pending.
Invitrogen Gateway® Technology: please see Limited Use Label License No. 19: Gateway® Cloning Products.
MATERIAL SAFETY DATA SHEET INFORMATION
To the best of our knowledge, these products do not require a Material Safety Data Sheet. However, all the properties of these products (and, if applicable, each of their components) have not been thoroughly investigated. Therefore, we recommend that you use gloves and eye protection, and wear a laboratory coat when working with these products.
|
|
Copyright 2002-2008 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, +7(495)4298020, e-mail:evrogen@evrogen.com |